Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Invesco Ltd.

Invesco Ltd. boosted its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 308.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,975,241 shares of the biotechnology company's stock after purchasing an additional 3,001,204 shares during the period. Invesco Ltd. owned approximately 1.39% of Exelixis worth $132,376,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Cerity Partners LLC boosted its stake in shares of Exelixis by 163.9% during the fourth quarter. Cerity Partners LLC now owns 73,884 shares of the biotechnology company's stock valued at $2,413,000 after purchasing an additional 45,890 shares in the last quarter. FMR LLC lifted its holdings in Exelixis by 19.7% during the fourth quarter. FMR LLC now owns 2,947,599 shares of the biotechnology company's stock worth $98,155,000 after buying an additional 485,527 shares during the period. Federated Hermes Inc. boosted its position in Exelixis by 82.9% during the 4th quarter. Federated Hermes Inc. now owns 408,932 shares of the biotechnology company's stock valued at $13,637,000 after acquiring an additional 185,389 shares in the last quarter. Hurley Capital LLC purchased a new position in shares of Exelixis in the 4th quarter valued at $68,000. Finally, Envestnet Asset Management Inc. raised its position in shares of Exelixis by 17.5% in the 4th quarter. Envestnet Asset Management Inc. now owns 200,228 shares of the biotechnology company's stock worth $6,668,000 after acquiring an additional 29,892 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several research firms have issued reports on EXEL. Royal Bank of Canada lifted their target price on Exelixis from $38.00 to $40.00 and gave the company an "outperform" rating in a research note on Thursday, March 13th. Stifel Nicolaus lifted their price objective on shares of Exelixis from $30.00 to $36.00 and gave the stock a "hold" rating in a research report on Wednesday, February 12th. JMP Securities reiterated a "market outperform" rating and set a $41.00 price objective on shares of Exelixis in a research note on Thursday, January 23rd. BMO Capital Markets downgraded shares of Exelixis from an "outperform" rating to a "market perform" rating and raised their target price for the company from $36.00 to $40.00 in a research note on Friday, December 20th. Finally, Brookline Capital Management began coverage on Exelixis in a research report on Monday, December 23rd. They set a "buy" rating on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $37.59.

Insider Buying and Selling

In other news, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total transaction of $388,000.00. Following the transaction, the executive vice president now owns 341,028 shares in the company, valued at $13,231,886.40. This trade represents a 2.85 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Bob Oliver sold 18,647 shares of Exelixis stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total transaction of $694,600.75. Following the completion of the sale, the director now owns 33,514 shares in the company, valued at approximately $1,248,396.50. This trade represents a 35.75 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 140,343 shares of company stock valued at $5,177,234. Corporate insiders own 2.85% of the company's stock.

Exelixis Trading Up 2.2 %

Shares of NASDAQ EXEL traded up $0.80 during trading on Tuesday, reaching $36.54. 2,242,333 shares of the company traded hands, compared to its average volume of 2,175,885. The stock has a market cap of $10.23 billion, a P/E ratio of 20.64, a PEG ratio of 1.13 and a beta of 0.57. The firm's fifty day simple moving average is $36.26 and its 200 day simple moving average is $34.09. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $40.02.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.